Gossamer Bio (GOSS) to Release Quarterly Earnings on Thursday

Gossamer Bio (NASDAQ:GOSS) will likely be issuing its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.19) per share and revenue of $6.3240 million for the quarter. Investors may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Monday, November 3, 2025 at 4:00 PM ET.

Gossamer Bio (NASDAQ:GOSS) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.01. The business had revenue of $11.49 million during the quarter, compared to analysts’ expectations of $4.12 million. Gossamer Bio had a negative net margin of 344.81% and a negative return on equity of 1,774.72%. On average, analysts expect Gossamer Bio to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Gossamer Bio Price Performance

GOSS stock opened at $2.39 on Thursday. The company has a 50 day simple moving average of $2.62 and a 200 day simple moving average of $1.80. The stock has a market cap of $543.44 million, a price-to-earnings ratio of -3.85 and a beta of 1.94. Gossamer Bio has a 1 year low of $0.66 and a 1 year high of $3.60.

Institutional Investors Weigh In On Gossamer Bio

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Legal & General Group Plc acquired a new stake in shares of Gossamer Bio in the second quarter valued at about $26,000. Banco BTG Pactual S.A. acquired a new stake in Gossamer Bio during the 2nd quarter valued at approximately $27,000. Lazard Asset Management LLC increased its position in Gossamer Bio by 53.9% during the 2nd quarter. Lazard Asset Management LLC now owns 67,362 shares of the company’s stock valued at $82,000 after purchasing an additional 23,601 shares during the period. Invesco Ltd. acquired a new stake in Gossamer Bio during the 1st quarter valued at approximately $48,000. Finally, Bank of America Corp DE increased its position in shares of Gossamer Bio by 107.2% during the fourth quarter. Bank of America Corp DE now owns 84,788 shares of the company’s stock worth $77,000 after buying an additional 43,866 shares during the period. Institutional investors and hedge funds own 81.23% of the company’s stock.

Wall Street Analysts Forecast Growth

GOSS has been the subject of several research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Gossamer Bio in a report on Thursday, September 11th. Scotiabank began coverage on Gossamer Bio in a report on Monday, July 14th. They issued a “sector outperform” rating and a $11.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Gossamer Bio in a report on Wednesday, October 8th. Wedbush upped their price objective on Gossamer Bio from $4.00 to $5.00 and gave the company an “outperform” rating in a research note on Wednesday, August 6th. Finally, Wall Street Zen downgraded Gossamer Bio from a “hold” rating to a “sell” rating in a research note on Sunday, September 21st. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Gossamer Bio presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.50.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.